Endocrine Abstracts

Objective: Transforming growth factor beta receptor 3 like (TGFBR3L) has been recently described as a pituitary-specific membrane protein detected in a proportion of the gonadotroph cells in non-neoplastic and tumour tissue (1). Furthermore, mouse studies have indicated that TGFBR3L is an inhibin B co-receptor that regulates FSH levels (2). We hypothesized that TGFBR3L expression in gonadotroph non-functioning pituitary neuroendocrine tumours (NF-PitNETs) is related to clinica...

Objective: Cushing’s disease is caused by hypercortisolism due to adrenocorticotropic hormone (ACTH) hypersecretion from functioning pituitary adenomas (FCA). Endoplasmic reticulum (ER) protein processing is important for hormone production and is upregulated in FCA as shown previously. ER protein processing can be disturbed by ER stress. We hypothesized that ACTH production and secretion can be inhibited by agents that cause ER stress by attenuating ER protein processing...

Introduction: The 2022 WHO classification identifies seven different pituitary tumour subtypes with growth hormone (GH) secretion and/or expression, with or without concurrent prolactin expression. The response to dopamine agonist (DA) treatment in these subtypes requires further investigation. The bromocriptine test has historically been a part of the acromegaly evaluation and may provide insights to DA treatment responsiveness. We aimed to explore the correlations between ba...

BackgroundCorticotroph pituitary adenomas present different degrees of functionality, from silent to whispering and finally to functioning adenomas leading to Cushing’s disease. Compared to their functioning (FCA) counterpart, the silent corticotroph adenomas (SCA) express lower levels of the corticotroph cell lineage marker–TBX19 (TPIT), proopiomelanocortin (POMC), and prohormone converting enzyme 1/3 (PC1/3, PCSK1)–t...